RxDoctor Payments DataLook up a doctor →

Gregg Berdy, MD

Ophthalmology · Saint Louis, MONPI 1376541540

Payments from drug & device makers

$739,551in general payments, 2019–2025

Across 758 payments — averaging $975.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch Health US, LLC$131K
  • Sun Pharmaceutical Industries Inc.$96K
  • Bausch & Lomb Americas Inc.$71K
  • Novartis$61K
  • AbbVie$57K
  • Kala Pharmaceuticals, Inc.$50K
  • plus $272K from 27 others

What the payments were for

  • Consulting fees$61,87317%
  • Speaking & faculty fees$245,06868%
  • Travel & lodging$33,6549%
  • Food & beverage$19,7975%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739,551 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$244,109
Medicare patients
550
Services billed
3,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj12$575,219
XiidraLifitegrast172$186,038
RestasisCyclosporine120$128,826
VyzultaLatanoprostene Bunod194$93,586
Lotemax SmLoteprednol Etabonate255$70,737
LumiganBimatoprost111$61,645
ProlensaBromfenac Sodium137$56,700
XdemvyLotilaner23$44,069
MieboPerfluorohexyloctane/Pf41$42,477
CequaCyclosporine44$36,966
RhopressaNetarsudil Mesylate57$30,917
AzasiteAzithromycin47$28,908
LotemaxLoteprednol Etabonate40$18,163
Cyclosporine19$11,736
VascepaIcosapent Ethyl34$10,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$44,753$575,21912 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo, Zirgan$71,296$329,995424 claims
AbbVieRestasis, Lumigan, Combigan$57,210$197,422250 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Lotemax, Besivance, Loteprednol Etabonate$37,489$155,634481 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$29,579$44,06923 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$25,482$41,33375 claims
Sun Pharmaceutical Industries Inc.Cequa$96,315$36,96644 claims
AlconSimbrinza$973$10,61727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →